Biomarker testing is key to unlocking precision medicine.
Biomarkers are often used to help determine the best treatment for a patient, but not all communities are benefitting from the latest advancements in biomarker testing and precision medicine.
Progress in improving cancer outcomes increasingly involves the use of precision medicine. Biomarker testing is an important step for accessing precision medicine including targeted therapies that can lead to improved survivorship and better quality of life for cancer patients. But without action to expand coverage of and access to biomarker testing, advances in precision medicine could increase existing disparities in cancer outcomes by race, ethnicity, income, and geography.
ACS CAN is working to expand insurance coverage of comprehensive biomarker testing.
Legislation enacted: AZ, IL, LA, RI, KY, NM, MD,MN, TX, GA, AR*, OK
Legislation passed in 2023: NY
Legislation introduced in 2023: CA,CT, CO, FL, MA, ME, NV, OH, PA (expected)
Get more information about our campaigns.